Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Amasten Fastighets AB in connection with a directed share issue
Mandate

Vinge has advised Amasten Fastighets AB in connection with a directed share issue

September 15, 2020 Capital Markets and Public M&A

Vinge has advised Amasten Fastighets AB (“Amasten”), a real estate company, in connection with a directed share issue whereby Amasten receives SEK 500 million in issue proceeds.

The subscription price was determined to SEK 7.30 per share through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The main purpose of the share issue is to finance continued growth through acquisitions of investment properties and development projects.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Malte St Cyr Ohm and Amanda M Johansson.

 

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025